Equities analysts expect that Hill-Rom Holdings, Inc. (NYSE:HRC) will announce sales of $707.80 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Hill-Rom’s earnings. The lowest sales estimate is $702.60 million and the highest is $716.20 million. Hill-Rom posted sales of $710.50 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.4%. The firm is expected to issue its next quarterly earnings results on Friday, April 26th.
According to Zacks, analysts expect that Hill-Rom will report full year sales of $2.88 billion for the current fiscal year, with estimates ranging from $2.87 billion to $2.89 billion. For the next fiscal year, analysts anticipate that the company will report sales of $2.97 billion, with estimates ranging from $2.95 billion to $3.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Hill-Rom.
Get Hill-Rom alerts:Hill-Rom (NYSE:HRC) last released its earnings results on Friday, January 25th. The medical technology company reported $1.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.04. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The company had revenue of $683.50 million during the quarter, compared to analysts’ expectations of $676.39 million. During the same period in the prior year, the business posted $0.92 EPS. The business’s revenue was up 2.1% on a year-over-year basis.
HRC has been the topic of several research analyst reports. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a research note on Saturday, January 19th. Morgan Stanley reduced their price objective on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. UBS Group initiated coverage on Hill-Rom in a research note on Tuesday, November 27th. They set a “buy” rating and a $115.00 price objective on the stock. Finally, Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $102.67.
Shares of HRC opened at $103.73 on Thursday. Hill-Rom has a 12-month low of $81.82 and a 12-month high of $108.10. The firm has a market cap of $6.97 billion, a P/E ratio of 21.84, a PEG ratio of 1.48 and a beta of 0.95. The company has a current ratio of 1.70, a quick ratio of 1.25 and a debt-to-equity ratio of 1.17.
Hedge funds and other institutional investors have recently modified their holdings of the business. Oregon Public Employees Retirement Fund increased its position in Hill-Rom by 8,755.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock worth $26,000 after buying an additional 2,281,991 shares during the period. Financial Gravity Companies Inc. acquired a new stake in Hill-Rom in the fourth quarter worth $48,000. Captrust Financial Advisors increased its position in Hill-Rom by 166.3% in the fourth quarter. Captrust Financial Advisors now owns 783 shares of the medical technology company’s stock worth $69,000 after buying an additional 489 shares during the period. IMS Capital Management acquired a new stake in Hill-Rom in the third quarter worth $71,000. Finally, Bronfman E.L. Rothschild L.P. increased its position in Hill-Rom by 47.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 907 shares of the medical technology company’s stock worth $80,000 after buying an additional 293 shares during the period. 82.41% of the stock is currently owned by hedge funds and other institutional investors.
About Hill-Rom
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Get a free copy of the Zacks research report on Hill-Rom (HRC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment